Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, clear lung pretreatment period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes: 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05430373
Study type Interventional
Source Grit Biotechnology
Contact Haifeng Qin, PhD
Phone +86 13601365243
Email hifo@263.net
Status Recruiting
Phase Phase 1
Start date May 23, 2022
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06404528 - Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours N/A
Terminated NCT04467853 - A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors Phase 1
Terminated NCT05698888 - Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors Phase 1
Recruiting NCT04587479 - A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT05472220 - Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Phase 1
Recruiting NCT05354323 - NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors Phase 1
Recruiting NCT04739293 - Study of ON 123300 in Patients With Advanced Cancer Phase 1
Not yet recruiting NCT05747339 - A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors N/A
Recruiting NCT05887492 - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05228015 - Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05018273 - Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors Phase 1
Recruiting NCT04621435 - Imaging of Solid Tumors Using FAP-2286 Phase 1
Recruiting NCT05861895 - A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors Phase 1
Recruiting NCT06088472 - TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors Early Phase 1
Recruiting NCT05768139 - First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Phase 1/Phase 2